These data led to our hypothesis that a core gene expression signature (GES) downstream of the KDM4A-PAF1 regulatory axis, is associated with AML patient outcomes compared with the known LSC score, LSC1717. The gene discussed is KDM4A; the disease is acute myeloid leukemia.